Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 173,493 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 173,493 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $18.15, for a total transaction of $3,148,897.95. Following the transaction, the director directly owned 9,682 shares of the company’s stock, valued at $175,728.30. The trade was a 94.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Down 1.2%

Shares of DYN stock traded down $0.22 during trading hours on Monday, hitting $18.04. 1,718,516 shares of the company’s stock traded hands, compared to its average volume of 2,147,507. Dyne Therapeutics, Inc. has a 12 month low of $8.06 and a 12 month high of $25.00. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. The stock’s 50 day simple moving average is $17.69 and its 200 day simple moving average is $18.46. The stock has a market cap of $2.98 billion, a PE ratio of -5.10 and a beta of 1.29.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -2.94 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on DYN. Wall Street Zen lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 28th. HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Morgan Stanley cut their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.14.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently added to or reduced their stakes in DYN. AQR Capital Management LLC bought a new stake in Dyne Therapeutics in the first quarter worth about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Dyne Therapeutics by 5.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after acquiring an additional 2,886 shares during the period. Goldman Sachs Group Inc. raised its position in Dyne Therapeutics by 58.2% in the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after acquiring an additional 366,183 shares during the period. Caxton Associates LLP bought a new stake in Dyne Therapeutics in the first quarter worth about $157,000. Finally, Creative Planning raised its position in Dyne Therapeutics by 23.8% in the second quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after acquiring an additional 2,797 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.